Danaher (DHR) Q1 FY25 earnings call

Danaher delivered a strong Q1 FY25, surpassing expectations driven by robust bioprocessing performance and elevated Cepheid respiratory demand. The company is navigating a dynamic macro environment with its durable business model and Danaher Business System, while proactively addressing structural costs and investing in long-term growth. Full-year guidance for core revenue growth remains at approximately 3%, with new adjusted EPS guidance provided.